Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human Albumin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    347 result(s) found for: Human Albumin. Displaying page 9 of 18.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2006-002695-17 Sponsor Protocol Number: DEB-025-HCV-203 Start Date*: 2006-09-21
    Sponsor Name:DEBIOPHARM S.A.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week i...
    Medical condition: treatment na ve patients with chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019744 Hepatitis C LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001245-24 Sponsor Protocol Number: GS-US-337-1118 Start Date*: 2014-10-01
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: An open-Label, multicenter study to evaluate the efficacy and safety of sofosbuvir/ledipasvir fixed-dose combination ± ribavirin for 12 or 24 weeks in chronic genotype 1 HCV infected subjects who p...
    Medical condition: Chronic Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000690-13 Sponsor Protocol Number: GS-US-337-1463 Start Date*: 2015-04-17
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults with Chronic HCV Infection.
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004713-24 Sponsor Protocol Number: GECOMstudy Start Date*: 2016-04-11
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 (Grazoprevir) / MK8742 (Elbasvir) Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection...
    Medical condition: Chronic infection with Hepatitis C virus genotype 1b with compensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002296-17 Sponsor Protocol Number: GS-US-337-0121 Start Date*: 2013-09-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for ...
    Medical condition: Chronic Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000968-34 Sponsor Protocol Number: CAMN107ADE20 Start Date*: 2015-10-07
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years o...
    Medical condition: The trial aims to evaluate the efficacy and quality of life of nilotinib 300mg BID in patients with chronic myleoid leukemia in chronic phase.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001081-42 Sponsor Protocol Number: HepNet-aHCV-IV Start Date*: 2014-10-21
    Sponsor Name:Hannover Medical School
    Full Title: Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study
    Medical condition: Adults with acute genotype 1 hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    18.1 10021881 - Infections and infestations 10065051 Acute hepatitis C PT
    18.1 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000519-26 Sponsor Protocol Number: 8951-CL-0302 Start Date*: 2019-02-13
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLD...
    Medical condition: Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NL (Completed) ES (Restarted) AT (Prematurely Ended) PT (Trial now transitioned) GR (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003102-14 Sponsor Protocol Number: IFG-NIB-01 Start Date*: 2017-09-19
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TR...
    Medical condition: Female patients with early, neoadjuvantly treated, triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021976 Inflammatory breast cancer stage IV LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071115 Node-negative breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021974 Inflammatory breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021975 Inflammatory breast cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063103 Tubular breast cancer stage I LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006194 Breast cancer NOS stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063104 Tubular breast cancer stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006196 Breast cancer NOS stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063102 Tubular breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006195 Breast cancer NOS stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063105 Tubular breast cancer stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054784 Contralateral breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021944 Infiltrating ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022882 Invasive ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006283 Breast neoplasm malignant female LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000533-22 Sponsor Protocol Number: LAL-CL08 Start Date*: 2014-05-28
    Sponsor Name:Alexion Pharmaceuticals Inc
    Full Title: A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency (LALD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10024579 Lysosomal storage disorders HLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-002121-35 Sponsor Protocol Number: GS-US-337-1406 Start Date*: 2014-10-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chroni...
    Medical condition: Chronic Genotype 1 and Genotype 4 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004063-36 Sponsor Protocol Number: CELIM-RCD-002 Start Date*: 2016-02-22
    Sponsor Name:Celimmune LLC
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Sm...
    Medical condition: Type II Refractory Celiac Disease (RCD-II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000630-17 Sponsor Protocol Number: MER-XMT-1536-1 Start Date*: 2021-09-21
    Sponsor Name:Mersana Therapeutics, Inc.
    Full Title: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
    Medical condition: High grade serous ovarian cancer or non-small cell lung cancer (NSCLC), adenocarcinoma subtype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) LT (Completed) CZ (Completed) HU (Completed) BG (Completed) FI (Completed) PL (Completed) DK (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001618-27 Sponsor Protocol Number: EMN14/54767414MMY3013 Start Date*: 2017-05-19
    Sponsor Name:Stichting European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing) BE (Completed) DE (Completed) CZ (Completed) DK (Completed) FR (Completed) NL (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002438-12 Sponsor Protocol Number: MRV01C Start Date*: 2007-09-21
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) whe...
    Medical condition: Combined Measles, Mumps, Rubella and Varicella Live Vaccine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000639 Active immunisation LLT
    9.1 10039242 Routine childhood immunisation LLT
    9.1 10036897 Prophylactic vaccination LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) NL (Not Authorised) DK (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003405-94 Sponsor Protocol Number: ABY-035-202 Start Date*: 2020-05-05
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003858-33 Sponsor Protocol Number: AM0010-301 Start Date*: 2017-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi...
    Medical condition: Advanced Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004742-11 Sponsor Protocol Number: 64007957MMY3001 Start Date*: 2021-10-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexame...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018240-23 Sponsor Protocol Number: CO-101-001 Start Date*: 2010-07-12
    Sponsor Name:Clovis Oncology Inc
    Full Title: A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) FR (Completed) GB (Completed) SE (Completed) DE (Completed) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005559-34 Sponsor Protocol Number: AIO-PAK-0313 Start Date*: 2015-01-19
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) A prospective, randomized, controlled, phase II st...
    Medical condition: Resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:18:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA